
Plexus (PLXS) Stock Forecast & Price Target
Plexus (PLXS) Analyst Ratings
Bulls say
Plexus Corp reported a consistent growth trajectory in its Healthcare/Life Sciences segment, with revenue increasing by 5% year-over-year, totaling $1.629 billion, and a forecast of high-single to low-double-digit growth in the upcoming quarters driven by multiple program ramps and recovering customer demand. Additionally, the Aerospace and Defense segment is expected to show sequential revenue growth of mid-single digits, supported by advancements in commercial air and unmanned aircraft programs, positioning the company to meet or exceed its overall revenue growth goal of 9-12% for fiscal year 2026. Overall, earnings are anticipated to outpace revenue growth significantly, highlighting continued operational leverage as Plexus's strategic initiatives unfold across its reportable segments.
Bears say
Plexus Corp has reported a decline in gross margin to 9.9%, down from 10.1% in the prior quarter, indicating potential challenges in maintaining profitability amidst increasing operational pressures. Revenue decline in the Aerospace & Defense segment, which constitutes 16% of total FQ4 revenues, of 6% both quarter-over-quarter and year-over-year raises concerns regarding demand stability in this critical market. Additionally, the company's expectations for a decrease in Industrial revenues in the upcoming quarter, combined with broader economic uncertainties and company-specific risks, point to a potentially challenging financial outlook for Plexus.
This aggregate rating is based on analysts' research of Plexus and is not a guaranteed prediction by Public.com or investment advice.
Plexus (PLXS) Analyst Forecast & Price Prediction
Start investing in Plexus (PLXS)
Order type
Buy in
Order amount
Est. shares
0 shares